Canada&s;s leading health care &a; life sciences venture capital firm with a 30-year reputation building companies across North America.
Business Model:
Revenue: $19M
Employees: 11-50
Address: 141 Adelaide Street
City: Toronto
State: ontario
Zip: M5H 3L5
Country: CA
With a 30-year reputation as a leading North American healthcare and life sciences venture capital firm, with offices in Toronto, Montreal, Vancouver and Boston, Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meeting significant unmet needs and creating transformation impact in communities worldwide. Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2013 | enGene | Venture Round | 13.3M |
5/2016 | Opsens | Post-IPO Equity | 5M |
2/2013 | BAROnova | Series C | 27.3M |
2/2018 | Exact Imaging | Series D | - |
12/2021 | OncoMyx Therapeutics | Series B | 0 |
1/2019 | enGene | Venture Round | - |
10/2021 | Deka Biosciences | Series A | 0 |
7/2015 | BAROnova | Venture Round | - |
9/2014 | Forbius | Venture Round | - |
9/2022 | Damona Pharmaceuticals | Seed Round | 0 |
9/2017 | Stellar Biotechnologies | Post-IPO Equity | 0 |
10/2018 | Pediapharm | Post-IPO Equity | 47.6M |
5/2017 | Forbius | Series B | - |
12/2019 | Bright Angel Therapeutics | Seed Round | - |
5/2016 | Osteopathy Quebec | Venture Round | - |
5/2017 | Osteopathy Quebec | Venture Round | - |
5/2011 | U-Systems | Venture Round | 0 |
2/2021 | Iterion Therapeutics | Series B | 17M |
12/2020 | Cyrano Therapeutics | Series A | 12.8M |
5/2020 | IMV Inc | Post-IPO Equity | 18M |
1/2023 | Cardiac Dimensions | Series D | 35M |
12/2007 | Cardiac Dimensions | Series D | 0 |
4/2018 | Cardiac Dimensions | Series B | 39M |
1/2015 | enGene | Series B | 0 |
11/2014 | OsteoQC Inc | Seed Round | - |
11/2018 | Gladius Pharmaceuticals | Venture Round | - |
6/2015 | Celtaxsys | Series D | 0 |
4/2019 | Bardy Diagnostics | Series B | 35.5M |
5/2020 | IMV | Post-IPO Equity | 25.1M |
12/2018 | Exact Imaging | Venture Round | - |
1/2018 | Exact Imaging | Venture Round | - |
1/2018 | Celtaxsys | Series E | - |
1/2017 | Exact Imaging | Series C | 16.3M |
6/2020 | HistoSonics | Series C | 40M |
11/2013 | Argos Therapeutics | Series E | 0 |
4/2012 | Argos Therapeutics | Series D | 0 |
9/2017 | Engage Therapeutics | Series A | 23.6M |
11/2017 | KalGene Pharmaceuticals | Series A | - |
5/2013 | Vendorlink.ca | Venture Round | - |
6/2018 | KisoJi Biotechnology | Series A | - |
9/2018 | Osteopathy Quebec | Venture Round | - |
11/2014 | Osteopathy Quebec | Seed Round | - |
12/2021 | Specific Biologics | Seed Round | - |
8/2021 | Thryv Therapeutics | Series A | 0 |
4/2021 | Antios Therapeutics | Series B | 0 |
2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
10/2022 | PIC Therapeutics | Series A | 35M |
11/2015 | Social Change Rewards | Venture Round | 2M |
1/2018 | KisoJi Biotechnology | Venture Round | - |
2/2022 | Congruence Therapeutics | Series A | 0 |
10/2008 | Pathfinder Therapeutics | Series A | 0 |
11/2015 | BAROnova | Series D | 36.5M |
11/2015 | First Aid Shot Therapy | Series C | 24M |
4/2014 | Cardiac Dimensions | Series A | 0 |
3/2021 | XyloCor Therapeutics | Series A | 0 |
6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
3/2013 | Corvia Medical | Series C | 10.7M |
4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
2/2021 | AmacaThera | Series A | 0 |
2/2015 | G1 Therapeutics | Series B | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
9/2013 | Aurinia Pharmaceuticals | Post-IPO Equity | 5.8M |
7/2016 | Endotronix | Series C | 0 |
12/2022 | HistoSonics | Convertible Note | 85M |
5/2021 | BioTheryX | Series E | 92M |
3/2015 | Vascular Pharmaceuticals | Series A | 9M |
10/2019 | AmacaThera | Seed Round | 2.7M |
2/2021 | Notch Therapeutics | Series A | 85M |
10/2014 | Cardiac Dimensions | Series A | 8.5M |
10/2012 | Thrasos | Series C | 35M |
4/2012 | Forbius | Series A | - |
7/2014 | Corvia Medical | Series D | 34M |
4/2019 | HistoSonics | Series C | 0 |
6/2015 | Gladius Pharmaceuticals | Series A | 3.3M |
3/2015 | Thrasos | Series D | 21M |
10/2016 | KisoJi Biotechnology | Series A | - |
3/2018 | KalGene Pharmaceuticals | Series A | 1.3M |
11/2018 | Antios Therapeutics | Series A | 0 |
9/2017 | Edesa Biotech | Series A | 7M |
5/2016 | G1 Therapeutics | Series C | 0 |
3/2015 | Cardiac Dimensions | Equity | 15.2M |
9/2018 | Endotronix | Series D | 0 |
9/2020 | Cardiac Dimensions | Series C | 17.5M |
12/2021 | Viron | Series B | 50M |
4/2023 | Antiva Biosciences | Series E | 0 |
6/2014 | Spinal Kinetics | Venture Round | 34M |
1/2016 | Zymeworks | Series A | 0 |
11/2021 | Antiva Biosciences | Series D | 0 |
6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
2/2022 | Congruence Therapeutics | Series A | 0 |
12/2021 | Specific Biologics | Seed Round | - |
12/2021 | OncoMyx Therapeutics | Series B | 0 |
12/2021 | Viron Inc. | Series B | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
11/2021 | Antiva Biosciences | Series D | 0 |
10/2021 | Deka Biosciences | Series A | 0 |
8/2021 | Thryv Therapeutics | Series A | 0 |
5/2021 | BioTheryX | Series E | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|